Antiviral susceptibilities to ganciclovir, foscarnet, and cidofovir and sequencing of UL97 and DNA polymerase were done on 23 cytomegalovirus (CMV) isolates from 10 immunocompromised persons with end-organ CMV disease who were treated with ganciclovir alone or ganciclovir followed by foscarnet. Screening of UL97 for ganciclovir resistance mutations was done by restriction digest analysis. Of 14 isolates resistant to ganciclovir, 11 (79%) contained one or more UL97 mutations at codons known to confer resistance to this compound, and 10 (91%) had a concordant mutant pattern by restriction digest analysis. Of 9 isolates containing mutations in conserved regions of the DNA polymerase, 8 were resistant to ganciclovir, and 4 were cross-resistant to cidofovir. All isolates were susceptible to foscarnet. It is concluded that ganciclovir-resistant clinical CMV isolates may contain UL97 mutations, DNA polymerase mutations, or mutations in both genes. Ganciclovir therapy may select for CMV isolates that are cross-resistant to cidofovir.
Cytomegalovirus (CMV) infections are a major cause of clinical CMV isolates, resistance to ganciclovir has been related to UL97 mutations at one or several loci [14 -22] . morbidity and mortality among immunocompromised patients, especially recipients of bone marrow and solid-organ trans-
The functional consequence of these UL97 mutations is impaired phosphorylation of ganciclovir in virus-infected cells, plants and patients with AIDS [1 -3] . Antivirals currently available for the treatment of CMV infections include ganciclovir, with the consequent lack of synthesis of ganciclovir triphosphate, the active form of the drug. Although the mechanisms foscarnet, and cidofovir [4, 5] . In severely immunocompromised patients with CMV disease, prolonged therapy is often of resistance to foscarnet have not yet been clearly elucidated, characterization of a small number of clinical CMV isolates necessary. A potential risk associated with prolonged use of antiviral compounds is the emergence of resistant viruses.
resistant to this compound has demonstrated the presence of single amino acid substitutions in conserved region II of the CMV isolates resistant to antivirals have been selected in the laboratory; they have amino acid deletions or substitutions in viral DNA polymerase [18] . CMV isolates cross-resistant to ganciclovir and foscarnet containing UL97 and DNA polymerconserved regions of the UL97 protein or point mutations in the DNA polymerase of the virus (or both) [6 -9] . Resistant ase mutations have been isolated from AIDS patients treated with both compounds [18] . CMV isolates resistant to cidofovir isolates have also been recovered from immunocompromised patients treated with anti-CMV compounds [10 -13] . In these have been selected in the laboratory. Characterization of these cidofovir-resistant isolates has shown the presence of DNA polymerase mutations, absence of UL97 mutations, cross-resistance to ganciclovir, and ability to induce phosphorylation of Received 21 August 1996; revised 6 December 1996. ganciclovir [8, 9] . promised patients with severe CMV disease who had been 
Materials and Methods
Reprints or correspondence: Dr. Alejo Erice, University of Minnesota, Box 609 UMHC, Harvard St. at East River Rd., Minneapolis, MN 55455.
Virus isolates. CMV isolates were selected from those avail-tissue culture flasks containing confluent monolayers of uninfected GGCG-3 (Z4958, reverse), 5-GGGCTCGAAACATCGTCAGG-3 (Z3583, forward) and 5-CGTGGCACGCCGTACTTCTT-3 human diploid fibroblasts. Aliquots of cell-associated viruses were prepared from flasks showing ú80% cytopathic effect and were (Z3584, reverse), 5-GTGATATCGAGGTAGACTGCGATG-3 (Pol1474, forward) and 5-GCGGCGGTAGAGATGATAGC-3 stored at 070ЊC in DMSO-containing medium until used in susceptibility studies.
(Pol2536, reverse), and 5-GTATCTACACCTCGCTGCTG-3 (Pol2401, forward) and 5-ACGGCAATGTGCGGCAGGTTAGAntiviral susceptibilities. Antiviral susceptibilities of CMV isolates were determined by a plaque-reduction assay (isolates 3 (Pol3895, reverse). PCR reactions were done under conditions similar to those described for the UL97 region. Amplified products from patients 1-3) [6] or by a DNA-DNA hybridization method (Diagnostic Hybrids, Athens, OH) [22] . Antivirals studied included were filter-purified and sequenced using multiple primers spaced at intervals of õ300 bases, Sequenase (United States Biochemicals, ganciclovir (provided by J. Verheyden; Syntex, Palo Alto, CA), foscarnet (provided by S. Martin-Munley; Astra USA, WestborCleveland) for manual sequencing, and the Prism kit (Applied Biosystems) for automated sequencing. DNA polymerase seough, MA), and cidofovir (provided by E. de Clercq; Rega Institute for Medical Research, Leuven, Belgium). The CMV laboratory quences were aligned with the AD169 reference sequence to determine whether mutations were present in the regions analyzed. strain AD169 was included in each assay as a susceptible control. CMV isolates with ganciclovir IC 50 values ú6 mM, foscarnet IC 50 Mutations were defined as base changes resulting in alteration of amino acid encoding as compared with CMV laboratory strains values ú400 mM, or cidofovir IC 50 values ú2 mM were considered resistant to these compounds.
AD169 and Towne. Sequencing of CMV UL97 region. Sequences representing codons 418-708 of UL97 were obtained by polymerase chain reaction (PCR), using DNA purified from fibroblasts infected with
Results

CMV isolates and primers designed on the basis of published data
Patients and virus isolates. Twenty-three CMV isolates on strain AD169. Primer sequences were 5-CATCGACGTTTC- were studied. All patients had CMV end-organ disease and had Amplified products were filter-purified and sequenced (Prism received treatment with ganciclovir (7 patients) or sequential Ready Reaction Dyedeoxy Terminator Cycle Sequencing Kit, Aptherapy with ganciclovir followed by foscarnet (3 patients). CMV therapy (8 isolates), at different time points during therate complete UL97 sequences. UL97 sequences were aligned with apy (12 isolates), or at autopsy (3 isolates). Clinical data and existing sequence data to detect previously described drug resistance mutations [14] [15] [16] [17] [18] [19] [20] [21] [22] . Amino acid changes not previously reresults of phenotypic and genotypic studies are summarized in ported in UL97 were also considered to be mutations. results of virologic studies from patients 1 -5 have been pre-UL97 mutations at codons 460 (Met-to-Val), 520 (Hist-to-Glu), sented in part elsewhere [10, 14, 15, 22] . , and 595 (Leu-to-Ser or -Phe) was done as preGanciclovir and foscarnet susceptibilities were determined viously described [14, 15] . In brief, PCR products obtained with for all 23 isolates, and cidofovir susceptibilities were also deterprimers CPT1088 and CPT1587M were screened for the V460 mined for 19 of the isolates. Of the 23 isolates, 14 from 8 and Q520 mutations by digesting with enzyme NlaIII or AluI, subjects were resistant to ganciclovir; the remaining 9 were respectively. Screening for the V594, S595, and F595 mutations susceptible to this compound. Four isolates from 2 subjects was done by digesting with HhaI, TaqI, and MseI PCR products showed decreased susceptibility to cidofovir, including 2 isoobtained with primers CPT1713 and CPT1830M. The presence of mutations was determined by distinctive restriction patterns lates that were clearly resistant to this compound. All CMV visualized by gel electrophoresis. Mutations at codons 460 and isolates were susceptible to foscarnet. 594 result in the loss of naturally occurring restriction enzyme Analysis of CMV UL97 region. Eleven (79%) of the 14 sites, whereas mutations at codons 520 and 595 create additional ganciclovir-resistant isolates contained UL97 mutations at loci restriction sites.
known to be related to resistance to this compound, including
Sequencing of CMV DNA polymerase region. Sequences ina Met-to-Val mutation at codon 460 (4 isolates), a His-to-Gln cluding codons 379-538, 696-845, 905-919, and 962-988, rep- mutation at codon 520 (2 isolates), a Cys-to-Gly mutation at resenting conserved regions I-VII and the region between IV and codon 592 (1 isolate), an Ala-to-Val mutation at codon 594 (4 A of the CMV DNA polymerase, were obtained by PCR, using isolates), an Ala-to-Thr mutation at codon 594 (1 isolate), and DNA purified from fibroblasts infected with CMV isolates and a Leu-to-Ser mutation at codon 595 (1 isolate). Whereas 9 of suitable primer pairs, such as 5-GCTGCACTTCGGAGGGTG-TGA-3 (Z4957, forward) and 5-TGCCGCTTAAAACCCACthe ganciclovir-resistant isolates contained single UL97 muta-/ 9d27$$my17 03-05-97 09:09:48 jinfa UC: J Infect NOTE. GCV Å ganciclovir; FOS Å foscarnet; HPMC Å cidofovir; CLL Å chronic lymphocytic leukemia; ND Å not determined; D Å mutation present at indicated codon; wt Å wild type sequence; Neg Å no mutation detected; BAL Å bronchoalveolar lavage fluid; Lung Å lung autopsy sample. None of the patients received GCV and FOS in combination; patients 4, 9, and 10 received GCV followed by FOS.
tions, 2 isolates (2B and 7B) had more than one mutation and a Gly-to-Ala mutation at codon 841 in conserved region III (3 isolates). Eight of the 9 isolates containing DNA polymerase in UL97. Three ganciclovir-resistant isolates (9A -C) did not contain any mutations in UL97 but did contain DNA polymermutations were resistant to ganciclovir, and 5 of these isolates also contained mutations in UL97. Four isolates (5B, 9A, 9B, ase mutations (see below). None of the ganciclovir-susceptible isolates contained UL97 mutations. and 9C) had reduced susceptibilities to cidofovir. Two of these (5B and 9C) were clearly cross-resistant to cidofovir, with IC 50 Restriction digest screening of UL97. Ten (91%) of the 11 isolates with the most common ganciclovir resistance UL97 values of ú10 mM and 6.2 mM, respectively. Whereas isolate 5B also had a Q520 mutation in UL97, the only mutations mutations demonstrated by sequencing had a concordant characteristic mutant pattern by restriction digest screening analyfound in isolates 9A -C were in the DNA polymerase (table  1) . sis. The restriction digest screening method missed the Q520 mutation in isolate 2B. This Q520 mutation consisted of a Analysis of sequential CMV isolates. Multiple CMV isolates from 3 subjects (patients 2, 4, and 9) were studied. In CAC-to-CAA base change (instead of a CAC-to-CAG change) that did not result in the creation of an additional AluI restriction addition to the isolates listed in table 1, 6 other isolates from patient 2 (all from blood samples) were included in the genosite and was not detected by the screening method at that codon [15] . typic studies (table 2) . Sequencing studies of the UL97 region showed that the initial CMV strain with a ganciclovir-resistant Analysis of CMV DNA polymerase region. DNA polymerase mutations were found in 9 isolates from 4 subjects, includphenotype from patient 2 contained a V460 mutation, with subsequent isolates showing the presence of a Q520 mutation ing an Asn-to-Asp mutation at codon 408 (3 isolates) and an Asp-to-Glu mutation at codon 413 (1 isolate) in conserved alternating or coexisting with a V594 mutation. In contrast, the same V460 mutation in UL97 was present in all ganciclovirregion IV, a Leu-to-Phe mutation at codon 501 (1 isolate) and a Pro-to-Ala mutation at codon 522 (3 isolates) between resistant CMV isolates from patient 4 (table 1). Only the first ganciclovir-resistant isolate from patient 4 contained an F501 conserved regions IV and A, a Thr-to-Ala mutation at codon 700 in conserved region II (1 isolate), a Glu-to-Asp mutation mutation in the DNA polymerase region, whereas the same A522 and A841 mutations were found in the DNA polymerase at codon 756 between conserved regions II and VI (1 isolate), / 9d27$$my17 03-05-97 09:09:48 jinfa UC: J Infect and cause resistance to these compounds is not known. It has been postulated that amino acid substitutions in those regions of the CMV polymerase could influence directly or indirectly regions of later isolates from this subject. All 3 isolates from the nucleotide binding capacity of the enzyme or could alter a patient 9 contained the same D408 mutation in the DNA polypossible 3j5 exonuclease function [8] . merase region, whereas the A700 mutation was only present Additional DNA polymerase mutations (at codons 522, 841, in the first isolate.
and 700) were found among other ganciclovir-resistant isolates in our study. Of note, none of these DNA polymerase mutants were cross-resistant to foscarnet. The isolates with DNA polyDiscussion merase mutations at codons 522 and 841 also contain a V460 mutation in UL97; therefore, the role of these DNA polymerase Our study indicates that ganciclovir-resistant clinical CMV isolates may contain UL97 mutations, DNA polymerase mutamutations in conferring resistance to ganciclovir is unclear.
The Thr-to-Ala mutation at codon 700 (conserved region II) has tions, or mutations in both genes. Most (79%) of the ganciclovir-resistant viruses we sequenced contained one or more been associated in previous studies with resistance to foscarnet, susceptibility to ganciclovir, and a slow-growth viral phenotype UL97 mutations at codons that have been characteristically associated with resistance to ganciclovir [16] . The strong clus- [18] . However, the isolate in our study containing a mutation at codon 700 was obtained prior to foscarnet therapy and was tering of UL97 mutations at codons 460, 520, and 591 -596 in resistant CMV isolates has led to the development of diagnostic susceptible to this compound. One of the isolates susceptible to all antivirals had a mutation at codon 756 (between conserved screening assays based on restriction enzyme digest analysis for rapid detection of the most common UL97 mutations conregions II and VI) in the DNA polymerase. A preliminary report has suggested that a different mutation at that codon ferring resistance to ganciclovir [14 -16] . However, as illustrated by the present study, this method did not detect a Q520 may be associated with resistance to foscarnet [23] . Clearly, additional studies are required to define the genetics and funcmutation with a base change that did not result in a mutant restriction enzyme pattern. In addition, the screening assay also tional significance of CMV DNA polymerase resistance mutations. The fact that all isolates included in our study were ''missed'' 3 ganciclovir-resistant viruses from 1 patient whose isolates contained DNA polymerase mutations but wild type susceptible to foscarnet suggests that DNA polymerase mutations conferring resistance to this compound are largely sepa-UL97 sequences. Therefore, whereas the majority of the ganciclovir-resistant viruses containing UL97 mutations can be rate from those conferring ganciclovir and cidofovir cross-resistance. detected by restriction digest analysis, a negative result does not necessarily indicate that a virus is susceptible to ganciclovir.
There is limited information regarding the persistence of CMV isolates containing UL97 or DNA polymerase mutations An important finding was the isolation of CMV isolates with reduced susceptibilities to cidofovir from patients who were never in vivo. In our study, the analysis of sequential CMV isolates from patients with multiple isolates illustrates several patterns treated with this compound. Genetic characterization of these isolates showed the presence of mutations in conserved region IV of acquisition and persistence. In patient 2, ganciclovir-resistant isolates containing three different UL97 mutations (V460, (codons 408 and 413) of the viral DNA polymerase. Although the functional significance of these DNA polymerase mutations Q520, and V594) were isolated from blood samples over a short period of time (table 2) . Although these results could be would require confirmation in recombinant studies, there is experimental evidence that mutations in this region cause resistance to the consequence of selection of a predominant isolate by culture, PCR, or both, they also indicate that multiple ganciclovirganciclovir and cross-resistance to cidofovir.
In one study, a Phe-to-Val mutation at codon 412 (conserved resistant isolates can coexist in the same person. These findings confirm previous data demonstrating that imregion IV) and a Leu-to-Ile mutation at codon 501 (between conserved regions IV and A) were found in the DNA polymerase munocompromised persons may have multiple CMV isolates / 9d27$$my17 03-05-97 09:09:48 jinfa UC: J Infect
